Kobayashi in ¥500 billion buyout talks after red-yeast case
CVC Capital Partners and Nippon Sangyo Suishin Kiko are weighing a bid to take the company private, sources said.
Japanese health products company Kobayashi Pharmaceutical is reportedly in talks for a potential buyout by private equity investors, with the offer valued at over ¥500 billion ($3.2 billion). CVC Capital Partners and Nippon Sangyo Suishin Kiko are among the parties considering a bid to take the company private, according to people with knowledge of the negotiations.
Kobayashi's founding family may also participate in the buyout, the sources added. The company received a preliminary, nonbinding joint proposal from the investors earlier this week, but no final decisions have been made yet. As of the market open in Tokyo, Kobayashi shares were not traded and were expected to rise.
Written by urgent.news from Japan Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
